Human Genome Sciences About
Human Genome Sciences Human Genome Sciences is a biopharmaceutical
company with a product pipeline derived primarily from proprietary genomic technology.
Their goal is to create a global biopharmaceutical company to discover, develop,
manufacture, and market gene-based protein and antibody
drugs to treat and cure disease. Products in clinical development focus
on two main therapeutic areas, immunology/infectious disease and oncology.The
core pipeline currently includes six products for use in the treatment of systemic
lupus, erythematosus, rheumatoid
arthritis, chronic hepatitis
C, and a variety of cancers such as non-small cell
lung cancer, colorectal
cancer and non-Hodgkin’s lymphoma.
Pipeline
for Human Genome
Sciences LymphoStat-B --specifically
recognizes and inhibits the biological activity of B-lymphocyte stimulator, or
BLyS™. --for autoimmune diseases e.g., lupus and rheumatoid arthritis Albuferon
-- a novel long-acting form of interferon alpha for the treatment of hepatitis
C, hepatitis B, and a broad range of cancers ABtrax -- Human
monoclonal antibody to bacillus anthracis protective antigen HGS-ETRI
-- anti-cancer drug that specifically binds to the TRAIL Receptor-1 protein
and triggers programmed cell death, or apoptosis, in cancer cells. HGS-ETR1 HGS-TR2J
-- agonistic human monoclonal antibody that specifically binds to the TRAIL
Receptor-2 protein -- causing apoptosis (cell death) in tumors. 480848
-- inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) an enzyme
associated with the formation of atherosclerotic plaques More
on Human
Genome Sciences Key
Statistics for Human Genome Sciences Analyst
Opinion
Basic
Chart for Human Genome Sciences
Analysts
Estimates